Iconovo is a leading Swedish CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. The company offers several patented inhaler platforms tailored for both generic and original drug formulations, enabling pharmaceutical partners to quickly bring cost-effective and user-friendly inhalation products to market.
Iconovo's advanced development pipeline includes ICOres®, a generic version of the asthma and COPD medication Symbicort®, expected to launch in 2025. Another major product, ICOpre®, is positioned to become the first generic challenger to the Ellipta® inhalation drug portfolio, with initial market entry anticipated in 2027.
